These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35398467)

  • 21. [Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].
    Adaleti R; Nakipoğlu Y; Arıcı N; Kansak N; Çalık Ş; Şenbayrak S; Balık R; Aksaray S
    Mikrobiyol Bul; 2023 Jul; 57(3):365-377. PubMed ID: 37462301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
    Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS
    J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
    Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
    J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.
    Deveci A; Coban AY; Acicbe O; Tanyel E; Yaman G; Durupinar B
    J Chemother; 2012 Oct; 24(5):247-52. PubMed ID: 23182043
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Goel A; Gupta V; Singhal L; Palta S; Chander J
    Indian J Med Res; 2021 Mar; 154(3):520-526. PubMed ID: 35345078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of synergistic activity of antibiotic combinations in extensive drug-resistant
    Abdel Halim RM; Saber SM; Fahim NAE
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36762530
    [No Abstract]   [Full Text] [Related]  

  • 29. Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
    Mohd Sazlly Lim S; Naicker S; Ayfan AK; Zowawi H; Roberts JA; Sime FB
    Int J Antimicrob Agents; 2020 Oct; 56(4):106115. PubMed ID: 32721600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019.
    Tuan Soh TS; Salvinder S; Chen VSY
    Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
    Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
    Vidaillac C; Leonard SN; Sader HS; Jones RN; Rybak MJ
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2360-6. PubMed ID: 19349512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae.
    Tian Y; Zhang Q; Wen L; Chen J
    Microbiol Spectr; 2021 Oct; 9(2):e0015221. PubMed ID: 34704782
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii.
    Gill CM; Santini D; Takemura M; Longshaw C; Yamano Y; Echols R; Nicolau DP
    J Antimicrob Chemother; 2023 Apr; 78(4):983-990. PubMed ID: 36775993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?].
    Ozseven AG; Sesli Çetin E; Ozseven L
    Mikrobiyol Bul; 2012 Jul; 46(3):410-20. PubMed ID: 22951653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of
    Suich J; Mawer D; van der Woude M; Wearmouth D; Burns P; Smeets T; Barlow G
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35476672
    [No Abstract]   [Full Text] [Related]  

  • 38. Synergistic activity of polymyxin B combined with vancomycin against carbapenem-resistant and polymyxin-resistant Acinetobacter baumannii: first in vitro study.
    Shinohara DR; Menegucci TC; Fedrigo NH; Migliorini LB; Carrara-Marroni FE; Maria Dos Anjos M; Cardoso CL; Nishiyama SAB; Tognim MCB
    J Med Microbiol; 2019 Mar; 68(3):309-315. PubMed ID: 30663954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-Avibactam Generates Diverse Resistance Mechanisms.
    Castanheira M; Lindley J; Doyle TB; Davis AP; Sader HS
    Int J Antimicrob Agents; 2023 Jan; 61(1):106698. PubMed ID: 36464152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.